Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 11;39:85. doi: 10.1186/s13046-020-01580-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — Caspase activity upon ULK1 inhibition in FLT3-ITD AML cells. a Cleaved caspase-3 and -9 and PARP levels were examined after treatment of MV4;11 cells and U937 cells with ULK1 inhibitors (MRT 68921; 2.5 μM, SBI-0206965; 5 μM) for 48 h by western blot analysis. α-Tubulin was used as a loading control. b After pre-treatment with the pan-caspase inhibitor z-VAD-fmk (20 μM), cells were treated with ULK1 inhibitors (MRT 68921; 2.5 μM, SBI-0206965; 5 μM). The fraction of apoptotic cells in MV4;11 cells and U937 cells was analyzed by flow cytometry based on Annexin-V/PI exclusion. c The MMP was quantified by measuring membrane potential-sensitive dye (DiOC6) intensity in MV4;11 and U937 cells after treatment of ULK1 inhibitors (MRT 68921; 2.5 μM, SBI-0206965; 5 μM). CTL, control. NS, not significant